Results 181 to 190 of about 21,551,551 (367)

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Diagnostic and Therapeutic Potential of Substance P/NK1 Receptor in Primary Dysmenorrhea: A Pilot Study. [PDF]

Health Sci Rep
Mehboob R, Shahid I, Alzahrani AR, Yousof SM, Adnan H, Ekram SN, Alwazzan A, Nasief H, Khadawardi KA.   +8 more
europepmc   +1 more source

Blocking substance P-signalling inhibits the IL-6 transcription induced by a single dwell in a rat model of PD

, 2016
Magnus Braide, Daniel Nilsson, Nicola Cavallini   +2 more
openalex   +1 more source

Substance P in heart failure: the good and the bad.

International Journal of Cardiology, 2014
Heather M Dehlin, S. Levick
semanticscholar   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Revisiting the role of Substance P and CGRPα. [PDF]

Elife
Cai W, Khoutorsky A.
europepmc   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Substance P [PDF]

Journal of Neurology, Neurosurgery & Psychiatry, 1977
openaire   +3 more sources

Ferrocenyl-Substituted Curcumin Derivatives as Potential SHP‑2 Inhibitors for Anticolorectal Cancer: Design, Synthesis and In Vitro Evaluation

ACS Omega
Xing-Ze Zhang, Gen Li, Gao-Yong Hu, Chen-Lin Wang, Yu-Qiu Fang, Yuye Li, Xue-Jie Qi, Lili Duan   +7 more
doaj   +1 more source

The role of substance P in Th17/Treg imbalance and ocular surface damage in chronic allergic conjunctivitis. [PDF]

J Transl Med
Bao J, Wen Y, Wu B, Li Y, Li S, Lei F, Tian L, Chen X, Jie Y.   +8 more
europepmc   +1 more source